Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 8:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Irritable Mood Clear all
Completed Not applicable Interventional Results available

Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder

NCT00617396
View directory record Official record
Conditions
Functional Bowel Disorders
Interventions
Quetiapine (50 mg/day-100mg/day)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 22, 2026, 8:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome

NCT03051204
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Irritable Bowel Syndrome, Celiac Disease, Healthy
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
4 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

SH-DS01 on Fecal Metagenomic Stability

NCT04598295
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DS-01
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT03596905
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Plecanatide, Matching placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 18 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
35
States / cities
Saraland, Alabama • Scottsdale, Arizona • Corona, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 22, 2026, 8:04 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Diet and Motility in IBS

NCT07283341
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Wireless Patch System
Diagnostic Test
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 22, 2026, 8:04 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Rifaximin With NAC in IBS-D

NCT06727422
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Interventions
rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 22, 2026, 8:04 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Visible Abdominal Distension

NCT06369753
View directory record Official record
Conditions
Irritable Bowel Syndrome, Dyspepsia, Functional Bloating
Interventions
Biofeedback, Placebo
Behavioral
Lead sponsor
Hospital Universitari Vall d'Hebron Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Phase 1Phase 2 Interventional

Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

NCT01890837
View directory record Official record
Conditions
Irritable Bowel Syndrome, Digestive System Diseases, Gastrointestinal Diseases, Intestinal Diseases, Abdominal Pain
Interventions
Daikenchuto (TU-100), Placebo
Drug
Lead sponsor
Tsumura USA
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 22, 2026, 8:04 PM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

NCT07545759
View directory record Official record
Conditions
Irritable Bowel Syndrome, Diarrhea
Interventions
LY3537031, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
15
States / cities
Mesa, Arizona • Anaheim, California • Lancaster, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cerebral Cortical Influences on Autonomic Function

NCT03869372
View directory record Official record
Conditions
Healthy Subjects, Functional Dyspepsia, Irritable Bowel Syndrome
Interventions
rTMS
Device
Lead sponsor
David Levinthal
Other
Eligibility
21 Years to 60 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

NCT02757105
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
BEKINDA, Placebo
Drug
Lead sponsor
RedHill Biopharma Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Huntsville, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Not applicable Interventional

Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome

NCT01094041
View directory record Official record
Conditions
Diarrhea, Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Gluten free diet, Gluten rich diet
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Sep 22, 2026, 8:04 PM EDT
Terminated Phase 4 Interventional Results available

Efficacy of Gralise® for Chronic Pelvic Pain

NCT01678911
View directory record Official record
Conditions
Irritable Bowel Syndrome, Ulcerative Colitis, Interstitial Cystitis, Prostatitis, Pelvic Pain
Interventions
Gralise
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT01880424
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Placebo, Linaclotide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
52
States / cities
Huntsville, Alabama • North Little Rock, Arkansas • Phoenix, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Not applicable Interventional

Smartphone Training for Attention Regulation for IBS

NCT05083091
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mindfulness and Attention Training, Mindfulness training, Coping Condition
Behavioral
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
359 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Not applicable Interventional

Brain Imaging and Pain in Irritable Bowel Syndrome

NCT00065754
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Phase 2 Interventional Results available

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

NCT02507284
View directory record Official record
Conditions
Irritable Mood, Huntington's Disease
Interventions
SRX246, Placebo
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Phase 3 Interventional Results available

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

NCT02621892
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
111
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Not applicable Interventional

Comparing Two Types of Diets on Psychological and Gastrointestinal Symptoms

NCT03035799
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Paleolithic diet, General Healthful Diet
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Phase 2 Interventional

A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome

NCT00486876
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Dextofisopam
Drug
Lead sponsor
Pharmos
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
79
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2011 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Not applicable Interventional

Pilot Study Using a Dietary Intervention for Children With Irritable Bowel Syndrome

NCT01018498
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Restricted FODMAPs diet
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Phase 2 Interventional

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

NCT00230581
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DDP225
Drug
Lead sponsor
Dynogen Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Scottsdale, Arizona • St Louis, Missouri • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2007 · Synced Sep 22, 2026, 8:04 PM EDT
Completed Not applicable Interventional

Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth

NCT02251483
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions
Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 22, 2026, 8:04 PM EDT
Completed No phase listed Observational

Cohort Study of Bowel Function Following Robotic-assisted Laparoscopic Sacrocolpopexy

NCT01618292
View directory record Official record
Conditions
Pelvic Organ Prolapse, Constipation, Bowel Dysfunction, Irritable Bowel Syndrome
Interventions
Robotic sacral colpopexy
Procedure
Lead sponsor
Atlantic Health System
Other
Eligibility
Female only
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 22, 2026, 8:04 PM EDT